April 22, 2009Blood87 citationsOpen Access
How I treat patients with myelodysplastic syndromes
Key Points
Key points are not available for this paper at this time.
Abstract
Critical issues in determining therapeutic strategies for patients with myelodysplastic syndromes (MDSs), who usually die of bone marrow failure with or without conversion to acute myeloid leukemia (AML), include host factors in these mainly older patients, disease heterogeneity, lack of